We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Measurable Residual Disease Assessed Post-Transplantation in Acute Lymphoblastic Leukemia

By LabMedica International staff writers
Posted on 07 Nov 2019
The detection of residual disease by techniques more sensitive than light microscopy is called measurable residual disease (MRD) and is an important prognostic marker, which dictates outcome of disease. More...
Assessment of measurable residual disease (MRD) is rapidly transforming the therapeutic and prognostic landscape of a wide range of hematological malignancies.

Its prognostic value in acute lymphoblastic leukemia (ALL) has been established and MRD measured at the end of induction is increasingly used to guide further therapy. Although MRD detectable immediately before allogeneic hematopoietic cell transplantation (HCT) is known to be associated with poor outcomes, it is unclear if or to what extent this differs with different types of conditioning.

An international team of hematologists and their colleagues led by Hammersmith Hospital (London, UK) carried out a multicenter, retrospective registry analysis of outcomes of 2,780 patients (median age 38 years, range 18–72) from 301 transplant centers who underwent first HCT in complete remission between 2000 and 2017 using sibling or unrelated donors. The team explored whether measurable residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) for ALL is associated with different outcomes in recipients of myeloablative total body irradiation (TBI)-based versus chemotherapy-based conditioning. The presence of Philadelphia chromosome status was collected.

The scientists reported that in 1,816 of patients, no disease was detectable, and in 964 patients, MRD was positive. Conditioning was TBI-based in 2,122 (76%) transplants. In the whole cohort MRD positivity was a significant independent factor for lower overall survival (OS) and leukemia-free survival (LFS), and for higher relapse incidence (RI), with respective hazard ratios (HR) of 1.19, 1.26, and 1.51. TBI was associated with a higher OS, LFS, and lower RI with HR of 0.75, 0.70, and 0.60, respectively.

No significant interaction was found between MRD status and conditioning. When investigating the impact of MRD separately in the TBI and chemotherapy-based conditioning cohorts by multivariate analysis, they found MRD positivity to be associated with lower OS and LFS and higher RI in the TBI group, and with higher RI in the chemotherapy group. TBI-based conditioning was associated with improved outcomes in both MRD-negative and MRD-positive patients.

The authors concluded that they had confirmed that patients who are MRD-negative prior to HCT achieve superior outcomes. This is particularly apparent if TBI conditioning is used. All patients with ALL irrespective of MRD status benefit from TBI-based conditioning in the myeloablative setting. The study was published on October 23, 2019, in the Journal of Hematology & Oncology.

Related Links:
Hammersmith Hospital


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: Increased polysialic acid in schizophrenia patients represents a potential diagnostic tool and possible target for treatment (Photo courtesy of 123RF)

New Technique for Measuring Acidic Glycan in Blood Simplifies Schizophrenia Diagnosis

Polysialic acid is a unique acidic glycan predominantly found in brain regions associated with memory and emotion, but it is also present in the bloodstream. Research has shown that blood levels of polysialic... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.